脐带间充质干细胞治疗脑梗死的安全性与有效性

目的:观察人脐带间充质干细胞(UC-MSC)治疗脑梗死的临床效果和安全性。方法:脑梗死患者1 20例,随机分为2组:对照组、UC-MSC治疗组,每组60例。对照组采用常规药物治疗+康复训练;UC-MSC治疗组在对照组治疗的基础上,给予UC-MS治疗。采用FIM评分及FMA评分对2组患者治疗前及后神经功能进行评定,并对患者年龄、病程、治疗前FMA评分与治疗后症状改善程度进行相关性分析。结果:治疗后1周、1月、3月FIM评分及FMA评分与治疗前相比,对照组差异均无统计学意义(P>0.05).治疗组中治疗前与治疗后1周比较,FIM评分及FMA评分差异无统计学意义(P>0.05);治疗前与治疗后1月比较,FMA评分升高(P<0.05),FIM评分差异无统计学意义(P>0.05);治疗前与治疗后3月比较,FIM评分、FMA评分升高,差异均有统计学意义(P<0.05)。治疗后3月,对照组与治疗组比较.FlM评分、FMA评分升高,差异均有统计学意义(P<0.05)。治疗组中患者年龄、病程与治疗后改善程度呈负相关(P<0.05),FMA评分与治疗后改善程度无相关性(P>0.05)。治疗组中在治疗后有16例患者出现轻度不良反应(发生率为26.67%):主要是轻度发热,轻度头昏头痛,腰部酸痛。36例(随访率60%)患者随访超过了1年,未见与细胞治疗相关的不良反应发生。结论:US-MSC鞘内注射联合静脉滴注治疗脑梗死后运动功能障碍疗效明显,同时具有良好的安全性。

Safety and Efficacy on the Treatment of Cerebral Infarction with Umbilical Cord Mesenchymal Stem Cells

Objective:To observe the effects on clinical efficacy and safety of umbilical cord mesenchymal stem cells(UC-MSCs) for cerebral infarction.Methods:A total of 120 cases of cerebral infarction were randomly divided into two groups for conventional treatment(control group) and UC-MSCs treatment(UC-MSC group),with 60 cases in each group.The FIM and FMA scoring were used to evaluate nerve function changes.The patients' age,disease course,FMA score before and after treatment were recorded and analyzed.Results:No changes in FIM and FMA scores were found in control group after treatment in three months.But FMA score increased significantly after UC-MSCs treatment for 1 month(P<0.05),and both FMA and FIM scores increased significantly after 3 months' treatment of UC-MSCs and higher than that respectively in control group(P<0.05).Age and course of disease,rather than FMA score,were related factors for the outcomes of UC-MSCs treatment(P<0.05).Mild adverse reactions such as fever,dizziness or headache,and lower back pain,were found in 16 cases after UC-MSCs treatment.There were 36 cases in UC-MSC group followed up for more than one year,and no serious adverse reaction occurred.Conclusion: US-MSC intrathecal injection combined with intravenous infusion shows curative effect with good safety in the treatment of motor dysfunction after cerebral infarction.